The cancellation of the Evonik IPO on Monday wasn’t a surprise for the new issues market but it was a disappointment. It re-opened old wounds — around the efficacy of advisers, the pricing expectations of political issuers and the structure of IPOs. But most of all it left the market bereft of the chance of new deals until after the summer break.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.